Cancer Research and Treatment

Volume 38(2); April 2006

Original Articles

Number of Radiation Oncologists in Korea, Adequate or Surplus?: Jin Oh Kang; Cancer Res Treat. 2006;38(2):61-65. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.61

Purpose

The purpose of this research is to discern and address the issues related to the radiation oncology manpower supply and its distribution.

Materials and Methods

The statistical data of the Annual Report of the Korea Central Cancer Registry (KCCR) from 1997 to 2002 and the Annual Report of the Korean Society of Radiation Oncology (KOSTRO) from 1997 to 2004 were used to predict the status of the human resources in 2015. The estimated demand and supply were calculated with the Microsoft Excel® program (Microsoft, Redmond, WA).

Results

The demand for radiation oncologists is estimated to be 161 in 2015 and about 4.9 radiation oncologists will be in demand annually. In contrast, an average of 15 new radiation oncologists will be supplied annually so that the accumulated surplus of radiation oncologists until 2015 is estimated to be 74.1. The main reason for the surplus comes from the discrepancy between the increased number of radiation therapy patients and the need for radiation oncologists. When there is an increase of 1,000 radiation therapy patients, the demand for radiation oncologists increases only by 2.4. This phenomenon is especially evident in the top 10 hospitals where the average number of radiation therapy patients per radiation oncologist is 341, which is 58% higher than the average number (215) of other 46 hospitals.

Conclusion

To prevent a surplus and to maintain the quality of management, the number of radiation therapy patients per radiation oncologist should be limited. Furthermore, coordinate control of the number of residency positions should be seriously considered.

Citations

Citations to this article as recorded by

Clinical Characteristics of Radiation Oncology in Korea during Past 10 Years
Young Hoon Ji, Mi Sook Kim, Haijo Jung, Seong Yul Yoo, Chul Koo Cho
Journal of Korean Medical Science.2009; 24(6): 1165. CrossRef

7,525 View
51 Download
1 Crossref

The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer: Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim; Cancer Res Treat. 2006;38(2):66-71. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.66

Abstract PDF PubReader ePub

Purpose

The authors conducted a multicenter study to evaluate the efficacy and safety of combination chemotherapy with Padexol® and cisplatin for treating patients with advanced non-small cell lung cancer (NSCLC).

Materials and Methods

From November 2003 to April 2005, 42 chemo-naive patients with advanced NSCLC were enrolled into this study from 4 hospitals. The treatment consisted of Padexol® 175 mg/m² as a 3-hr infusion, and this was followed by cisplatin 75 mg/m² administered as an intravenous infusion with standard premedication. The treatment was repeated every 3 weeks.

Results

Among the 42 patients (pts), 33 pts were evaluable for response. On the per protocol analysis, 1 patient (pt) (3.0%) achieved complete response (CR), 17 pts (51.5%) achieved partial response (PR), 6 pts (18.2%) achieved stable disease (SD), and 9 pts (27.3%) progressed; therefore, the overall response rate was 54.6% (95% CI: 37.6~71.5%). On the intention-to-treat analysis, 1 pt (2.4%) achieved CR, 18 pts (42.9%) achieved PR, 11 pts (26.2%) achieved SD, and 9 pts (21.4%) progressed; therefore, the overall response rate was 45.2% (95% CI: 30.2~60.3%). The response, as evaluated by the investigators, was independently reviewed by 2 external radiologists and it was as follows; 13 PR (43.3%), 14 SD (46.7%) and 3 progressive disease (10%). The median duration of response was 5.9 months. The median follow-up duration was 10.3 months (range: 1.3 to 22.1 months). The median time to progression was 5.8 months (95% CI: 4.7 to 7.4 months). The median survival time on the intention-to-treat analysis was 10.5 months (95% CI: 8.1 to 18.8 months). The most common grade 3 or 4 hematologic toxicities were neutropenia (26/180 cycles, 14.4%), anemia (7/180 cycles, 3.9%) and febrile neutropenia (2/180 cycles, 1.1%). The most frequent grade 3 or 4 non-hematologic toxicities were nausea (14/42 patients, 14.3%), anorexia (3/42 patients, 7.1%) and myalgia (3/42 patients, 7.1%).

Conclusion

The authors observed that Padexol® was as good as the other paclitaxel (Taxol® or Genexol®) formulations when combined with cisplatin for treating patients with advanced NSCLC.

Citations

Citations to this article as recorded by

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
Puyuan Xing, Yixiang Zhu, Ling Shan, Sipeng Chen, Xuezhi Hao, Junling Li
Oncotarget.2017; 8(50): 87442. CrossRef
Efficacy and Safety of Weekly Low Dose Paclitaxel and Cisplatin as First Line Therapy in Advanced NSCLC of Elderly Patients
Jung Ho Lee, Mi Hye Kwon, Ji Hyun Jeoung, Go Eun Lee, Eu Gene Choi, Moon Jun Na, Hyun Min Cho, Young Jin Kim, Weon Kuu Chung, Young Jun Cho, Ji Woong Son
Journal of Lung Cancer.2007; 6(2): 85. CrossRef

9,955 View
49 Download
2 Crossref

A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer: Sang-Byung Bae, Nam-Su Lee, Han-Jo Kim, Kyoung-Ha Kim, Hyun-Jung Kim, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park; Cancer Res Treat. 2006;38(2):72-77. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.72

Abstract PDF PubReader ePub

Purpose

We prospectively conducted a non-randomized phase II trial to evaluate the efficacy and safety of combination irinotecan, leucovorin (LV) and 5-fluorouracil (FU) as a first-line regimen for treating patients with previously untreated advanced colorectal cancer (CRC).

Materials and Methods

Twenty-six previously untreated patients with advanced, recurrent or metastatic CRC were enrolled in this study. The patients received either irinotecan 180 mg/m² on day 1 with LV bolus of 200 mg/m² and FU bolus of 400 mg/m², and this was followed by FU continuous infusion of 600 mg/m² on day 1 and day 2 (the FOLFIRI regimen), or they were treated with LV bolus of 400 mg/m² and FU bolus of 400 mg/m² followed by FU continuous infusion of 2,400 mg/m² for 46 hours (the simplified FOLFIRI regimen), and these treatments were repeated every 2 weeks until disease progression.

Results

The objective response rate was 23.1% (6/26) respectively, for both treatments. The median time to progression was 5.3 months (range: 0.4~19.9), and the overall survival was 11.2 months (range: 0.5~52.3). The prognostic factor for longer survival was the Eastern Cooperative Oncology Group (ECOG) performance status (PS). The non-hematological toxicities were similar for both treatment groups, with more frequent grade ≥3 neutropenia being noted for the simplified FOLFIRI regimen.

Conclusion

The biweekly irinotecan based regimen was demonstrated to have a moderate antitumor activity with acceptable toxicity profiles, and the ECOG PS was the independent prognostic factor.

Citations

Citations to this article as recorded by

Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
Louise André, Gabriel Antherieu, Amélie Boinet, Judith Bret, Thomas Gilbert, Rabia Boulahssass, Claire Falandry
Cancers.2022; 14(10): 2470. CrossRef
The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab
B. Budai, T. Nagy, I. Láng, E. Hitre
Angiogenesis.2013; 16(1): 113. CrossRef
Successful Treatment of Small-Cell Lung Cancer With Irinotecan in a Hemodialysis Patient With End-Stage Renal Disease
Dong Min Kim, Hyun Lee Kim, Choon Hae Chung, Chi Young Park
The Korean journal of internal medicine.2009; 24(1): 73. CrossRef

12,119 View
68 Download
3 Crossref

Efficacy of Combined Gemcitabine/Cisplatin Chemotherapy for Locally Advanced or Metastatic Urothelial Cancer: Kwan-Sik Bae, Kyu Il Ahn, Seung Hyun Jeon, Jung-Sik Huh, Sung-Goo Chang; Cancer Res Treat. 2006;38(2):78-83. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.78

Abstract PDF PubReader ePub

Purpose

We wanted to determine and report on the outcome of combined gemcitabine/cisplatin chemotherapy for patients suffering with locally advanced or metastatic urothelial cancer.

Materials and Methods

Between July 1999 and December 2004, 43 selected patients were enrolled in this study. Group 1 (the adjuvant chemotherapy group) had undergone radical surgery with removal of evident tumor from the following primary sites: bladder (n=8), renal pelvis (n=7) and ureter (n=3). Group 2 (the salvage chemotherapy group) had undergone palliative surgery with a remnant tumor at the following primary sites; bladder (n=23) and renal pelvis (n=2). All the patients were given gemcitabine/ciplatin and they evaluated for the therapeutic effect and toxicity. The patients were initially treated with gemcitabine 1000 mg/m² intravenously for 30 minutes on days 1, 8 and 15 of a 28-day cycle, and cisplatin 70 mg/m² was administered intravenously on day 1 using prehydration measures.

Results

Group 1: The median follow-up period was 16.5 months. The mean age was 63 years (males: 15 cases, females: 3 cases), and eleven patients (61%) remained alive. The estimated median relapse-free survival period and 2-year survival rate were 24 months and 63%, respectively. Group 2: the median follow-up period was 20 months, the mean patient age was 63.8 years (males: 22 cases, females: 3 cases), and nine patients (36%) remained alive. The overall response and 2-year survival rates were 36% and 43%, respectively. Toxicities: Grade 3 toxicities developed in 14 cycles during the total 232 cycles. Grade 4 toxicity did not occur.

Conclusions

The results of this study confirm that adjuvant and salvage chemotherapy with using gemcitabine and cisplatin is tolerable and safe.

Citations

Citations to this article as recorded by

Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
Ioannis Boukovinas, Nikolaos Androulakis, Nikolaos Kentepozidis, Aris Polyzos, Pavlos Papakotoulas, Nikolaos Ziras, Athanasios Kotsakis, Nikolaos Vardakis, Athanasios Karampeazis, Vassilis Markos, Athanasios Kostakopoulos, Constantine A. Constantinides, G
Cancer Chemotherapy and Pharmacology.2012; 69(2): 351. CrossRef

9,203 View
41 Download
1 Crossref

Evaluation of Parotid Gland Function following Intensity Modulated Radiation Therapy for Head and Neck Cancer: Seok Ho Lee, Tae Hyun Kim, Joo Young Kim, Sung Yong Park, Hong Ryull Pyo, Kyung Hwan Shin, Dae Yong Kim, Joo Young Kim, Kwan Ho Cho; Cancer Res Treat. 2006;38(2):84-91. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.84

Abstract PDF PubReader ePub

Purpose

This study was undertaken to determine the parotid gland tolerance dose levels following intensity modulated radiation therapy (IMRT) for treating patients who suffered with head and neck cancer.

Materials and Methods

From February 2003 through June 2004, 34 head and neck patients with 6 months of follow-up were evaluated for xerostomia after being treated by IMRT. Their median age was 59 years (range: 29~78). Xerostomia was assessed using a 4-question xerostomia questionnaire score (XQS) and a test for the salivary flow rates (unstimulated and stimulated: USFR and SSFR, respectively). The patients were also given a validated LENT SOMA scale (LSS) questionnaire. Evaluations were performed before IMRT and at 1, 3 and 6 months after IMRT.

Results

All 34 patients showed significant changes in the XQS, LSS and Salivary Flow rates (USFR and SSFR) after IMRT. No significant changes in the XQS or LSS were noted in 12 patients who received a total parotid mean dose of ≤3,100 cGy at 1, 3 and 6 months post-IMRT relative to the baseline values. However, for the 22 patients who received >3,100 cGy, significant increases in the XQS and LSS were observed. The USFR and SSFR from the parotid glands in 7 patients who received ≤2,750 cGy were significantly preserved at up to 6 months after IMRT. However, the USFR and SSFR in 27 patients who were treated with >2,750 cGy were significantly lower than the baseline values at all times after IMRT.

Conclusion

We suggest that the total parotid mean dose should be limited to ≤2,750 cGy to preserve the USFR and SSFR and so improve the subsequent quality of life.

Citations

Citations to this article as recorded by

Evaluation of the Effect of Photobiomodulation on Radiation-Induced Xerostomia in Head and Neck Cancer Patients: A Randomized Clinical Trial
Pegah Mosannen Mozaffari, Zahra Delavarian, Reza Fekrazad, Azar Fani Pakdel, Mahdokht Rashed Mohassel, Mohammad Taghi Shakeri, Ala Ghazi
Journal of Lasers in Medical Sciences.2024; 15: e4. CrossRef
Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer
Marcell Costa de Medeiros, Stephanie The, Emily Bellile, Nickole Russo, Ligia Schmitd, Erika Danella, Priyanka Singh, Rajat Banerjee, Christine Bassis, George R. Murphy, Maureen A. Sartor, Isabelle Lombaert, Thomas M. Schmidt, Avi Eisbruch, Carol Anne Mur
Microbiome.2023;[Epub] CrossRef
Translation and cross-cultural adaption of the Chinese version of the Vanderbilt Head and Neck Symptom Survey version 2.0: a tool for oral symptom assessment in head and neck cancer patients
Min Jin, Li Sun, Rui Meng, Wenjing Wang, Rui Sun, Jing Huang, You Qin, Bian Wu, Qian Ding, Gang Peng, Tao Zhang, Kunyu Yang
Health and Quality of Life Outcomes.2021;[Epub] CrossRef
Study of dosimetry and clinical factors for assessment of xerostomia in head and neck squamous cell carcinoma treated by intensity-modulated radiotherapy: A prospective study
Vrinda Singla, Vipul Nautiyal, Meenu Gupta, Viney Kumar, Shivani Mehra, Mushtaq Ahmad
Journal of Carcinogenesis.2021; 20(1): 14. CrossRef
Radiotherapy-related quality of life in patients with head and neck cancers: a meta-analysis
Xiuhong Ge, Zhengluan Liao, Jianhua Yuan, Dewang Mao, Yumei Li, Enyan Yu, Xunheng Wang, Zhongxiang Ding
Supportive Care in Cancer.2020; 28(6): 2701. CrossRef
Xerostomia, salivary characteristics and gland volumes following intensity‐modulated radiotherapy for nasopharyngeal carcinoma: a two‐year follow up
CPC Sim, YL Soong, EPP Pang, C Lim, GD Walker, DJ Manton, EC Reynolds, JTS Wee
Australian Dental Journal.2018; 63(2): 217. CrossRef
Radiotherapy changes salivary properties and impacts quality of life of children with Hodgkin disease
L. Marangoni-Lopes, L.P. Rodrigues, R.H. Mendonça, M. Nobre-dos Santos
Archives of Oral Biology.2016; 72: 99. CrossRef
Is linac-based volumetric modulated arc therapy better than helical tomotherapy in the radiotherapy of nasopharyngeal carcinoma?
Vincent W. C. Wu, Bing-kin Choi, Ho-nam Chan, Ruby Lam, Yu-king Wong, Alan W. L. Mui, George Chiu
Journal of Radiation Oncology.2015; 4(1): 29. CrossRef
Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers: A Triple-Blind, Randomized, Placebo-Controlled Trial
Abbas Javadzadeh Bolouri, Atessa Pakfetrat, Arghavan Tonkaboni, Seyed Amir Aledavood, Mohsen Fathi Najafi, Zahra Delavarian, Mohammad Taghi Shakeri, Azade Mohtashami
Iranian Journal of Cancer Prevention.2015;[Epub] CrossRef
Evaluation of an automated knowledge based treatment planning system for head and neck
Jerome Krayenbuehl, Ian Norton, Gabriela Studer, Matthias Guckenberger
Radiation Oncology.2015;[Epub] CrossRef
Translation and validation of the Chinese version of the quality of life radiation therapy instrument and the head & neck module (QOL-RTI/H&N)
Xin-lin Chen, Zhen-wen Qiu, Mo-fa Gu, Yong Su, Li-zhi Liu, Yan Liu, Chuan-wei Mo, Qian Xu, Juan Sun, Dong-hai Li
Health and Quality of Life Outcomes.2014;[Epub] CrossRef
Correlation of Parotid Gland Function in Head and Neck Cancer Patients treated with Intensity-modulated Radiotherapy
Sonal Vahanwala, Sukhjinder Kaur Khosa, Sandeep S Pagare
International Journal of Head and Neck Surgery.2012; 3(1): 1. CrossRef
Effects of Intensity-modulated Radiotherapy on Human Oral Microflora
Zi-Yang SHAO, Zi-Sheng TANG, Chao YAN, Yun-Tao JIANG, Rui MA, Zheng LIU, Zheng-Wei HUANG
Journal of Radiation Research.2011; 52(6): 834. CrossRef

15,523 View
107 Download
13 Crossref

Overexpression of α1-protease Inhibitor and Galectin-1 in Radiation-induced Early Phase of Pulmonary Fibrosis: Hee-Soon Im, Hyung-Doo Kim, Jie-Young Song, Youngsoo Han, Do-Youn Lee, Chan-Wha Kim, Yeon-Sook Yun; Cancer Res Treat. 2006;38(2):92-98. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.92

Abstract PDF PubReader ePub

Purpose

Radiation-induced pulmonary fibrosis (RIF) is a significant complication of radiotherapy for lung cancer. Despite the large number of studies, the molecular mechanisms of RIF are poorly understood. Therefore, the complex protein expression pattern in RIF was characterized by identifying the proteins with an altered expression level after thorax irradiation using two-dimensional electrophoresis (2-DE) and mass spectrometry.

Materials and Methods

A mouse model of RIF was used to examine the alteration of the lung proteome because of availability of murine data related to human cases and the abundance of murine fibrotic lung samples. A mouse model of RIF was induced in radiosensitive C57BL/6 mice. Twenty-one weeks after 25 Gy irradiation, hematoxylin-eosin staining and hydroxyproline assay confirmed the early-phase pulmonary fibrosis.

Results

Lung samples from the irradiated and age-matched control mice were used to generate 16 high quality 2-DE gels containing approximately 1,000 spots. Of the 31 significantly up- or down-regulated protein spots, 17 were identified by MALDI-TOF/MS.

Conclusions

Two important upregulated proteins were found, the α1-protease inhibitor and galectin-1, which might be used as potential markers for the early phase of RIF.

Citations

Citations to this article as recorded by

Gal-1-mediated cytochrome p450 activation promotes fibroblast into myofibroblast differentiation in pulmonary fibrosis
Jie Weng, Qianhui Cheng, Jingwen Yang, Haijuan Jin, Ran Zhang, Jiangan Guan, Yuan Ma, Liang Wang, Chan Chen, Zhiyi Wang
International Immunopharmacology.2024; 141: 112920. CrossRef
Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives
Chien-Hsiu Li, Yu-Chan Chang, Ming-Hsien Chan, Yi-Fang Yang, Shu-Mei Liang, Michael Hsiao
Biomedicines.2021; 9(9): 1159. CrossRef
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis
David Bennett, Elena Bargagli, Nicola Bianchi, Claudia Landi, Antonella Fossi, Annalisa Fui, Piersante Sestini, Rosa Metella Refini, Paola Rottoli
Respiratory Physiology & Neurobiology.2020; 273: 103323. CrossRef
Tissue- and cell-specific localization of galectins, β-galactose-binding animal lectins, and their potential functions in health and disease
Junko Nio-Kobayashi
Anatomical Science International.2017; 92(1): 25. CrossRef
Induction of galectin-1 by TGF-β1 accelerates fibrosis through enhancing nuclear retention of Smad2
Min Jin Lim, Jiyeon Ahn, Jae Youn Yi, Mi-Hyoung Kim, A-Rang Son, Sae-lo-oom Lee, Dae-Seog Lim, Sung Soo Kim, Mi Ae Kang, Youngsoo Han, Jie-Young Song
Experimental Cell Research.2014; 326(1): 125. CrossRef

10,070 View
51 Download
5 Crossref

Protein Expression Profile using Two-Dimensional Gel Analysis in Squamous Cervical Cancer Patients: Su-Mi Bae, Hyun-Jin Min, Guo Hua Ding, Sun-Young Kwak, Young-Lae Cho, Kye-Hyun Nam, Choong Hak Park, Yong-Wan Kim, Chong-Kook Kim, Byoung-Don Han, Young-Joo Lee, Do Kang Kim, Woong-Shick Ahn; Cancer Res Treat. 2006;38(2):99-107. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.99

Abstract PDF PubReader ePub

Purpose

Screening in cervical cancer is now progressing to discover candidate genes and proteins that may serve as biological markers and that play a role in tumor progression. We examined the protein expression patterns of the squamous cell carcinoma (SCC) tissues from Korean women with using two- dimensional polyacrylamide gel electrophoresis (2-DE) and matrix assisted laser desorption/ionization-time of flight (MALDI- TOF) mass spectrometer.

Materials and Methods

Normal cervix and SCC tissues were solubilized and 2-DE was performed using pH 3~10 linear IPG strips of 17 cm length. The protein expression was evaluated using PDQuest 2-D software™. The differentially expressed protein spots were identified with a MALDI-TOF mass spectrometer, and the peptide mass spectra identifications were performed using the Mascot program and by searching the Swiss-prot or NCBInr databases.

Results

A total of 35 proteins were detected in SCC. 17 proteins were up-regulated and 18 proteins weredown-regulated. Among the proteins that were identified, 12 proteins (pigment epithelium derived factor, annexin A2 and A5, keratin 19 and 20, heat shock protein 27, smooth muscle protein 22 alpha, α-enolase, squamous cell carcinoma antigen 1 and 2, glutathione S-transferase and apolipoprotein a1) were protein previously known to be involved in tumor, and 21 proteins were newly identified in this study.

Conclusion

2-DE offers the total protein expression profiles of SCC tissues; further characterization of these differentially expressed proteins will give a chance to identify the badly needed tumor-specific diagnostic markers for SCC.

Citations

Citations to this article as recorded by

Integrative machine learning frameworks to uncover specific protein signature in neuroendocrine cervical carcinoma
Tao Shen, Tingting Dong, Haiyang Wang, Yi Ding, Jianuo Zhang, Xinyi Zhu, Yeping Ding, Wen Cai, Yalan Wei, Qiao Wang, Sufen Wang, Feiyun Jiang, Bin Tang
BMC Cancer.2025;[Epub] CrossRef
The role of proteomics in the modern diagnosis of cervical cancer
Aida U. Hamadyanova, Azalia S. Sultanmuratova, Aliya Kh. Disbiyanova, Svetlana N. Akhmadeyeva, Nikita O. Yadgarov, Liana E. Burangulova
Journal of obstetrics and women's diseases.2022; 71(2): 113. CrossRef
Understanding Cervical Cancer through Proteomics
Fátima Martínez-Rodríguez, Jared E. Limones-González, Brenda Mendoza-Almanza, Edgar L. Esparza-Ibarra, Perla I. Gallegos-Flores, Jorge L. Ayala-Luján, Susana Godina-González, Eva Salinas, Gretel Mendoza-Almanza
Cells.2021; 10(8): 1854. CrossRef
Annexin A1 peptide and endothelial cell‐conditioned medium modulate cervical tumorigenesis
Laila Toniol Cardin, Janesly Prates, Bianca Rodrigues da Cunha, Eloiza Helena Tajara, Sonia Maria Oliani, Flávia Cristina Rodrigues‐Lisoni
FEBS Open Bio.2019; 9(4): 668. CrossRef
Assessment of cellular and serum proteome from tongue squamous cell carcinoma patient lacking addictive proclivities for tobacco, betel nut, and alcohol: Case study
Sapna Khowal, Samar H. Naqvi, Seema Monga, Swatantra K. Jain, Saima Wajid
Journal of Cellular Biochemistry.2018; 119(7): 5186. CrossRef
iTRAQ-based quantitative proteomic analysis of cervical cancer
YIBING DING, MIN YANG, SHA SHE, HAIYAN MIN, XIAOMING XV, XIAOPING RAN, YONGZHENG WU, WEI WANG, LEI WANG, LONG YI, YIXUAN YANG, QIAN GAO
International Journal of Oncology.2015; 46(4): 1748. CrossRef
Differential expression analysis of Golgi apparatus proteomes in hepatocellular carcinomas and the surrounding liver tissues
Yaying Yang, Yi Luo, Xiujun Li, Yongfen Yi
Hepatology Research.2014; 44(5): 542. CrossRef
Regulation of cell survival by the HIP-55 signaling network
Chengzhi Yang, Zenggang Li, Zhi Shi, Kangmin He, Aiju Tian, Jimin Wu, Youyi Zhang, Zijian Li
Molecular BioSystems.2014; 10(6): 1393. CrossRef
Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs
Zijian Li, Hae Ryon Park, Zhi Shi, Zenggang Li, Cau Dinh Pham, Yuhong Du, Fadlo R. Khuri, Youyi Zhang, Qide Han, Haian Fu
Oncotarget.2014; 5(10): 3197. CrossRef
Role-Shifting PKCζ Fosters Its Own Proapoptotic Destruction by Complexing with Bcl10 at the Nuclear Envelope of Human Cervical Carcinoma Cells: A Proteomic and Biochemical Study
Anna Chiarini, Maddalena Marconi, Raffaella Pacchiana, Ilaria Dal Prà, Jun Wu, Ubaldo Armato
Journal of Proteome Research.2012; 11(8): 3996. CrossRef
Annexin A5 protein expression is associated with the histological differentiation of uterine cervical squamous cell carcinoma in patients with an increased serum concentration
XIN LI, LONG CHEN, XIU JUN LIANG, YU FENG GAO, XIAO JIE WANG, QIAN XU, YONG YAN, FU LU GAO
Molecular Medicine Reports.2012; 6(6): 1249. CrossRef
Altered Carcinogenesis and Proteome in Mammary Glands of Rats after Prepubertal Exposures to the Hormonally Active Chemicals Bisphenol A and Genistein
Angela M. Betancourt, Jun Wang, Sarah Jenkins, Jim Mobley, Jose Russo, Coral A. Lamartiniere
The Journal of Nutrition.2012; 142(7): 1382S. CrossRef
Modeling microRNA-mRNA Interactions Using PLS Regression in Human Colon Cancer
Xiaohong Li, Ryan Gill, Nigel GF Cooper, Jae Keun Yoo, Susmita Datta
BMC Medical Genomics.2011;[Epub] CrossRef
α‐enolase: a promising therapeutic and diagnostic tumor target
Michela Capello, Sammy Ferri‐Borgogno, Paola Cappello, Francesco Novelli
The FEBS Journal.2011; 278(7): 1064. CrossRef
Glucose‐regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer
Chia‐Jung Liao, Tzu‐I Wu, Ya‐Hui Huang, Ting‐Chang Chang, Chia‐Siu Wang, Ming‐Ming Tsai, Chyong‐Huey Lai, Ying Liang, Shih‐Ming Jung, Kwang‐Huei Lin
Cancer Science.2011; 102(12): 2255. CrossRef
Identification of Cervical Cancer Proteins Associated With Treatment With Paclitaxel and Cisplatin in Patients
Huiling Liu, Yin Han, Ruoran Mi, Ying Zhang, Gang Su, Hailin Wang, Xin Zhou, Xiangwen Liu, Bingdong Zhu
International Journal of Gynecological Cancer.2011; 21(8): 1452. CrossRef
Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract
Geert Zegels, Geert AA Van Raemdonck, Wiebren AA Tjalma, Xaveer WM Van Ostade
Proteome Science.2010;[Epub] CrossRef
Candidate Molecules Identified by Proteomic Study of Synovial Cells in Experimental Post-Traumatic Arthritis of Knee in Swine
O. Baatartsog, K. Choi, P.K. Mandal, H.K. Lim, J.D. Oh, S.H. Chang
Biotechnology(Faisalabad).2008; 8(1): 13. CrossRef

12,285 View
68 Download
18 Crossref

Hydrogen Peroxide Producing Lactobacilli in Women with Cervical Neoplasia: Ho Sun Choi, Ki Min Kim, Chol Hong Kim, Seok Mo Kim, Jong Seok Oh; Cancer Res Treat. 2006;38(2):108-111. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.108

Abstract PDF PubReader ePub

Purpose

It is well known that human papillomavirus (HPV) is the main cause of cervical neoplasia, and hydrogen peroxide-producing lactobacilli are the most important microorganisms for maintaining the balance of the vaginal ecosystem. The purpose of our study was to investigate the relationship of hydrogen peroxide-producing lactobacilli, cervical neoplasia and high-risk HPV.

Materials and Methods

We enrolled 1138 women with abnormal cervical smears or cervicograms who were referred to the department of Obstetrics and Gynecology at Chonnam National University Medical School. In all of them, 1,138 vaginal swabs were collected for the qualitative assay of hydrogen peroxide producing lactobacilli and 150 cervical swabs were used for the HPV hybrid capture II test without regard to the subjects' pregnancy status. In the non-pregnant women, 880 cervical biopsies and/or loop electrosurgical excision procedures were performed for making the histological diagnosis.

Results

There was no significant difference not only between the distribution of H₂O₂ producing lactobacilli and the cervical histology, but also between the distribution of H₂O₂ producing lactobacilli and the positivity for high-risk HPV.

Conclusions

Both cervical neoplasia and high-risk HPV may not be influenced by the existence of hydrogen peroxide producing lactobacilli in the vagina.

Citations

Citations to this article as recorded by

Unravelling the Biological Interplay Between Genital HPV Infection and Cervicovaginal Microbiota in Sub-Saharan Africa: Implications for Cervical (Pre)cancer Prevention
Harris Onywera, Zizipho Z. A. Mbulawa, Adrian Brink, Anna-Lise Williamson, Lamech M. Mwapagha
Venereology.2024; 3(4): 211. CrossRef
Antimicrobial activity of Lactobacillus against microbial flora of cervicovaginal infections
Subramanyam Dasari, Raju Naidu Devanaboyaina Shouri, Rajendra Wudayagiri, Lokanatha Valluru
Asian Pacific Journal of Tropical Disease.2014; 4(1): 18. CrossRef
PCR‐based identification of eight lactobacillus species and 18 hr‐HPV genotypes in fixed cervical samples of south african women at risk of HIV and BV
Joke A.M. Dols, Gregor Reid, Remco Kort, Frank H.J. Schuren, Hugo Tempelman, Tj. Romke Bontekoe, Hans Korporaal, E.M. Van der Veer, Pieter W. Smit, Mathilde E. Boon
Diagnostic Cytopathology.2012; 40(6): 472. CrossRef

9,462 View
80 Download
3 Crossref

Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3-kinase Inhibition in the Human Cervical Cancer Cell-line: Jung Kyu Park, Chi Heum Cho, Sabarish Ramachandran, So Jin Shin, Sang Hoon Kwon, Sun Young Kwon, Soon Do Cha; Cancer Res Treat. 2006;38(2):112-117. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.112

Abstract PDF PubReader ePub

Purpose

Sodium butyrate (NaBT) is principally a histone deacetylase (HDAC) inhibitor, and it has the potential to arrest HPV-positive carcinoma cells at the G1 to S phase transition of the cell cycle. The aim of study was to determine whether phosphatidylinositol 3-kinase (PI3K) inhibition can enhance the inhibitory effect of NaBT on a human cervical cancer cell line (HeLa).

Materials and Methods

Cervical cancer cells (HeLa) were treated with NaBT alone or in combination with the PI3K inhibitors wortmannin or LY294002. Cell viability analysis and FACS analysis were carried out. The expressions of the cell cycle related proteins were evaluated by Western-blot analysis.

Results

Inhibition of PI3K enhanced NaBT-mediated apoptosis and this decreased the HeLa cell viability. Either wortmannin or LY294002, combined with NaBT, enhanced the activation of caspase 3 and caspase 9, and this enhanced the subsequent cleavage of poly (ADP-ribose) polymerase (PARP). Cervical cancer cells were arrested in the subG1 and G2/M phase, as was detected by FACS analysis. NaBT treatment in combination with PI3K inhibitors showed the increased expression of the CDK inhibitors p21^Cip1/Waf1 and p27^Kip1, in a p53 dependent manner, and also the increased dephosphorylation of Rb whereas there was a reduction in the expression levels of cyclin A, cyclin D1 and cyclin B1.

Conclusion

The results demonstrate that inhibition of PI3K enhances NaBT-mediated cervical cancer cell apoptosis through the activation of the caspase pathway. Moreover, these findings will support future investigation using the PI3K inhibitors in combination with adjuvant treatment for treating carcinoma of the cervix.

Citations

Citations to this article as recorded by

Targeting Cervical Cancer Stem Cells by Phytochemicals
Tanya Tripathi, Joni Yadav, Divya Janjua, Apoorva Chaudhary, Udit Joshi, Anna Senrung, Arun Chhokar, Nikita Aggarwal, Alok Chandra Bharti
Current Medicinal Chemistry.2024; 31(32): 5222. CrossRef
Human papillomavirus molecular prevalence in south China and the impact on vaginal microbiome of unvaccinated women
Tingting Wang, Weili Li, Mingya Cai, Shushen Ji, Yufang Wang, Nan Huang, Yancheng Jiang, Zhishan Zhang, Jack A. Gilbert
mSystems.2024;[Epub] CrossRef
Butyrate as a Potential Modulator in Gynecological Disease Progression
Nayeon Kim, Changwon Yang
Nutrients.2024; 16(23): 4196. CrossRef
The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
Iason Psilopatis, Nikolaos Garmpis, Anna Garmpi, Kleio Vrettou, Panagiotis Sarantis, Evangelos Koustas, Efstathios A. Antoniou, Dimitrios Dimitroulis, Gregory Kouraklis, Michail V. Karamouzis, Georgios Marinos, Konstantinos Kontzoglou, Afroditi Nonni, Kon
Cancers.2023; 15(8): 2222. CrossRef
Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus
Natália Lourenço de Freitas, Maria Gabriela Deberaldini, Diana Gomes, Aline Renata Pavan, Ângela Sousa, Jean Leandro Dos Santos, Christiane P. Soares
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Guanine nucleotide binding protein like-1 (GNL1) promotes cancer cell proliferation and survival through AKT/p21 CIP1 signaling cascade
Rehna Krishnan, Mariappan Murugiah, Naga Padma Lakshmi,, Sundarasamy Mahalingam, Carl-Henrik Heldin
Molecular Biology of the Cell.2020; 31(26): 2904. CrossRef
Cellular Effects of Butyrate on Vascular Smooth Muscle Cells are Mediated through Disparate Actions on Dual Targets, Histone Deacetylase (HDAC) Activity and PI3K/Akt Signaling Network
Omana P. Mathew, Kasturi Ranganna, Joseph Mathew, Meiling Zhu, Zivar Yousefipour, Chelliah Selvam, Shirlette G. Milton
International Journal of Molecular Sciences.2019; 20(12): 2902. CrossRef
The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy
Afsane Bahrami, Malihe Hasanzadeh, Seyed Mahdi Hassanian, Soodabeh ShahidSales, Majid Ghayour‐Mobarhan, Gordon A. Ferns, Amir Avan
Journal of Cellular Biochemistry.2017; 118(12): 4163. CrossRef
The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways
Igor Hrgovic, Monika Doll, Johannes Kleemann, Xiao-Fan Wang, Nadja Zoeller, Andreas Pinter, Stefan Kippenberger, Roland Kaufmann, Markus Meissner
BMC Cancer.2016;[Epub] CrossRef
The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses
Lifang Zhang, Jianhong Wu, Ming Tat Ling, Liang Zhao, Kong-Nan Zhao
Molecular Cancer.2015;[Epub] CrossRef
Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells
Elzbieta Pastwa, Tomasz Poplawski, Urszula Lewandowska, Stella B. Somiari, Janusz Blasiak, Richard I. Somiari
The International Journal of Biochemistry & Cell Biology.2014; 53: 423. CrossRef
The Role of Signaling Pathways in Cervical Cancer and Molecular Therapeutic Targets
Joaquín Manzo-Merino, Adriana Contreras-Paredes, Elenaé Vázquez-Ulloa, Leticia Rocha-Zavaleta, Alma M. Fuentes-Gonzalez, Marcela Lizano
Archives of Medical Research.2014; 45(7): 525. CrossRef
A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma
TAKESHI YAMADA, MANO HORINAKA, MASAHIDE SHINNOH, TAKASHI YOSHIOKA, TSUNEHARU MIKI, TOSHIYUKI SAKAI
International Journal of Oncology.2013; 43(4): 1080. CrossRef
Cytoplasmic translocation of p21 mediates NUPR1‐induced chemoresistance
Andrew J. Vincent, Suping Ren, Lillianne G. Harris, Daniel J. Devine, Rajeev S. Samant, Oystein Fodstad, Lalita A. Shevde
FEBS Letters.2012; 586(19): 3429. CrossRef
Effect of butyrate on aromatase cytochrome P450 levels in HT29, DLD-1 and LoVo colon cancer cells
Agnieszka Anna Rawłuszko, Sylwia Sławek, Armin Gollogly, Katarzyna Szkudelska, Paweł Piotr Jagodziński
Biomedicine & Pharmacotherapy.2012; 66(2): 77. CrossRef
Targeting Interleukin-4 Receptor α with Hybrid Peptide for Effective Cancer Therapy
Liying Yang, Tomohisa Horibe, Masayuki Kohno, Mari Haramoto, Koji Ohara, Raj K. Puri, Koji Kawakami
Molecular Cancer Therapeutics.2012; 11(1): 235. CrossRef
Butyrate Induces Expression of 17β-Hydroxysteroid Dehydrogenase Type 1 in HT29 and SW707 Colorectal Cancer Cells
Agnieszka Anna Rawłuszko, Piotr Krokowicz, Paweł Piotr Jagodziński
DNA and Cell Biology.2011; 30(9): 661. CrossRef
Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells
J. Ciura, P. P. Jagodziński
Molecular Biology Reports.2010; 37(8): 3729. CrossRef
Bean (Phaseolus vulgaris L.) polysaccharides modulate gene expression in human colon cancer cells (HT-29)
R. Campos-Vega, R.G. Guevara-Gonzalez, B.L. Guevara-Olvera, B. Dave Oomah, G. Loarca-Piña
Food Research International.2010; 43(4): 1057. CrossRef
N-Hydroxy-7-(2-naphthylthio) Heptanomide Inhibits Retinal and Choroidal Angiogenesis
Jeong Hun Kim, Jin Hyoung Kim, Meeyeon Oh, Young Suk Yu, Kyu-Won Kim, Ho Jeong Kwon
Molecular Pharmaceutics.2009; 6(2): 513. CrossRef

10,887 View
59 Download
20 Crossref

Case Report

A Case of Recurrent Solid Pseudopapillary Tumor of the Pancreas with Involvement of the Spleen and Kidney: Sang Eun Park, Nam Sook Park, Jae Min Chun, Nam Whan Park, Young Joon Yang, Gak Won Yun, Hyo Jin Lee, Hwan Jung Yun, Deog Yeon Jo, Kyu Sang Song, Samyong Kim; Cancer Res Treat. 2006;38(2):118-120. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.118

Abstract PDF PubReader ePub

Solid pseudopapillary tumor of the pancreas (SPTP) is a rare primary pancreatic tumor of an unknown etiology that is usually diagnosed in adolescent girls and young women. Most SPTPs are considered to be benign and only rarely metastasize. We report here on a 27-year old woman with recurrent SPTP with involvement of both the spleen and left kidney at the time of the initial diagnosis, and with aggressive behavior. In July 1995, she was admitted with abdominal discomfort and mass. She underwent exploratory laparotomy with distal pancrea tectomy, left nephrectomy and splenectomy, and was diagnosed with SPTP with invasion to both the spleen and left kidney. In June 2001, she again presented with abdominal pain and was diagnosed as having recurrence of the tumor. She underwent mass excision and omentectomy. Then she was lost to follow-up. In November 2005, she presented once again with an abdominal mass and was diagnosed with recurred SPTP, which formed a huge intraperitoneal mass with peritoneal seeding and the tumor showed multiple metastases in the liver. She is currently being treated conservatively.

Citations

Citations to this article as recorded by

Clinical Pattern of Preoperative Positron Emission Tomography/Computed Tomography (PET/CT) Can Predict the Aggressive Behavior of Resected Solid Pseudopapillary Neoplasm of the Pancreas
Ji-Su Kim, Emmanuel II-Uy Hao, Seoung-Yoon Rho, Ho-Kyoung Hwang, Woo-Jung Lee, Dong-Sub Yoon, Chang-Moo Kang
Cancers.2021; 13(9): 2119. CrossRef

8,312 View
42 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Previous issues